- Home
- TSAT vs ALLO Comparison
TSAT vs ALLO Comparison
Compare TSAT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSAT | ALLO |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 707.6M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TSAT | ALLO |
|---|---|---|
| Price | $37.42 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $37.00 | $8.35 |
| AVG Volume (30 Days) | 202.6K | ★ 9.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.59 | $0.99 |
| 52 Week High | $59.12 | $4.46 |
Technical Indicators
Market Signals| Indicator | TSAT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 37.18 |
| Support Level | $28.22 | $1.56 |
| Resistance Level | $43.82 | $1.92 |
| Average True Range (ATR) | 2.61 | 0.11 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 16.65 | 5.62 |
Price Performance
Historical ComparisonAbout TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).